Skip to main content

Catalyst Calendar

Scope

Tue, Oct 6, 2026

1 updates

Wed, Sep 30, 2026

1 updates
OCGN
7:02 AM

Ocugen to Participate in Upcoming Scientific Conferences

MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming

Presentation / Abstract • Phase 1/2Euretina podium presentation Thu, Oct 1, 2026, 1:00 PM CESTocugen.com

Tue, Sep 29, 2026

1 updates
OCGN
7:02 AM

Ocugen to Participate in Upcoming October Investor and Industry Conferences

MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership team will present at two upcoming investor and industry

ocugen.com

Fri, Sep 25, 2026

1 updates
OCGN
7:02 AM

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP) within 90 days, following full approval by the Longevity and Regenerative Therapies Board (LARTA

ocugen.com

Tue, Sep 1, 2026

1 updates
OCGN
7:02 AM

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

The single global Phase 3 trial, ArMaDa3 ( NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA) U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) designation, providing enhanced agency engagement throughout development

Trial Start • Phase 3Trial initiation Tue, Sep 1, 2026ocugen.com

Tue, Aug 25, 2026

1 updates
OCGN
7:02 AM

Ocugen to Participate in Upcoming September Investor and Industry Conferences

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and

Presentation / Abstract • Phase 2Retina Society presentation Thu, Sep 24, 2026, 3:15 PM PSTocugen.com